SHANGHAI, Nov. 28, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it is scheduled to present at the following investor conferences in December 2011:
Ms. Lan Xie, Vice President of Finance and Investor Relations of ShangPharma, will present at the following conferences:
-- Deutsche Bank 5th Annual MedTools Investor Summit, December 5-6, 2011,
-- Oppenheimer 22nd Annual Healthcare Conference, December 13-14, 2011, New
Presentation materials will be available under the Webcasts & Presentations section of the Company's investor relations website at http://ir.shangpharma.com.
ABOUT SHANGPHARMA CORPORATION
ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.
For further information, please contact:
Ms. Lan Xie
VP of Finance and Investor Relations
SOURCE ShangPharma Corporation